Kompier, L.C.

mutation patient recurrence bladder cancer tumor surveillance bladder cancer fgfr 3 fgfr 3 mutations grade tumours analysis tumour stage pik 3ca mutations wild-type cystoscopy assay urine pik 3ca study group progression status fgfr 3 mutation detection van der kwast factor figure fgfr 3 status ras mutations nmi-bc modi fied surveillance follow-up growth receptor bladder tumors frequency urine samples kinase mutation status carcinoma mutation assays sample pathway urothelial strategy number therapy urothelial cell carcinoma cystosc 257 patients wild-type recurrences john wiley zwarthoff ec 2 years recurrence rates disease-specific survival p 53 overexpression erasmus mc zwarthoff oncogene survival kirkels wj signi ficantly mi-bc transurethral resection domain ficial bladder cancer volume pik 3ca genes month 54 patients table ras genes panel november issue model